Navigation Links
New Lung Cancer Drug Launched By Roche Pharmaceutical

Major Pharmaceutical Company Roche launched its anti-cancer drug `Tarceva' (erlotinib), which `prolongs and improves' quality of life of patients//, suffering from lung cancer.

The Managing Director Dr G L Telang said, it was an oral tablet taken once a day and has the potential to treat many types of solid tumours therapy for patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) even after failure of at least one prior chemotherapy regiment.

Dr. Telang also said that, the drug has demonstrated a striking survival benefit (42.5 per cent) in advanced non-small cell lung cancer, the most common form of the disease and it has also shown to significantly improve patients' quality of life by reducing the severe and debilitating symptoms that characterise advanced disease, such as cough, pain and breathlessness.

Tarceva works differently to chemotherapy by specifically targeting tumour cells and inhibiting their growth. The drug blocks the tumour cell growth. It acts by inhibiting the activity of a specific enzyme, tyrosine kinase, which is part of the human epidermal growth receptor (EGFR).

Regarding the registration of the drug in the country, they have applied to the government for registration and expect it to come through by the end of this year, he said. Dr.Telang said that the drug will be sold 40 per cent below the international cost and if the government removes the duty on the drug, then the price will be further reduced. He also stated by using the drug, the life of the patient would extends up to a year.

Dr.Telang said, that they were also focusing on trials on earlier stages of NSCLC and in combination with another anti-cancer drug of Roche 'avastin. Trials are also being conducted with Tarceva in other solid tumours like ovarian, bronchioloalveolar and colorectal, head, neck and brain.


'"/>




Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... million people suffering from acne, access to quality care can be limited while the ... skincare company that offers customized prescription acne care for every customer online, today released ...
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
(Date:3/28/2017)... ... ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders and ... to the discussion of dealing with excess skin oil. “Oily skin is a challenge to ... can help remove the oily shine while keeping the skin fresh and clean,” says Dr. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
(Date:3/27/2017)... March 27, 2017  A new survey ... that Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary ... The lack of choice forces beneficiaries to switch to ... health consequences. AADE,s survey is the ... and others pointing out the inherent problems with the ...
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
Breaking Medicine Technology: